Clinical Profile and Short Term Outcome of Adult Patients with Acute Myeloid Leukemia

  • Sherin Jacob
  • Sajini Elizabeth Jacob
  • Bettadpura Shamanna SuryanarayanaEmail author
  • Tarun Kumar Dutta
Original Article


Acute myeloid leukemia has a poor outcome because of early deaths, high relapse rate and financial constraints. Our hospital provides care free of cost and this study assesses the short term outcome of acute myeloid leukemia in adults. The study was done from September 2013 to May 2015. All patients above 18 years of age were included. Cytarabine infusion 100 mg/m2 daily for 7 days and Daunorubicin 60 mg/m2 daily for 3 days was used for induction chemotherapy followed by three cycles of high dose cytarabine as post-remission therapy. One hundred and two patients were included in the study. 48% were males. The median age was 41 years. There was an intention to treat in 84 patients. 13 patients died before chemotherapy and 71 patients (57 non AML M3) received induction chemotherapy. 82% of them had a Eastern Cooperative Oncology Group performance score of ≤ 2. 28 (of 57 non AML M3) patients were alive after post-remission therapy (with 39% deaths during induction phase) and 15 of them were in remission after a median follow up of nine months. The overall event free survival at the end of the study was 22% (16 out of 71). Altogether, 63 out of 84 patients had died. Sepsis was considered as the cause of death in 46% of the patients, but the isolation of causative organism was limited (20%). The treatment outcomes of AML are poor at our centre and the current standard of care needs a significant improvement.


Acute myeloid leukemia Resource limited settings Short term outcome 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Acute myeloid leukemia—SEER Stat Fact Sheets. Accessed 21 July 2018
  2. 2.
    Bertoli S, Tavitian S, Huynh A, Borel C, Guenounou S, Luquet I et al (2017) Improved outcome for AML patients over the years 2000–2014. Blood Cancer J 7:635CrossRefGoogle Scholar
  3. 3.
    Saikia TK, Bakshi A, Bhagwat R (2005) Outcome of acute myeloid leukemia in adults: a retrospective analysis. Natl Med J India 18:12–15PubMedGoogle Scholar
  4. 4.
    Philip C, George B, Ganapule A, Korula A, Jain P, Alex A et al (2015) Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol 170:110–117CrossRefGoogle Scholar
  5. 5.
    Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642–4649CrossRefGoogle Scholar
  6. 6.
    Ghosh S, Shinde SC, Kumaran GS (2003) Hematologic and immunophenotypic profile of acute myeloid leukemia: an experience of Tata Memorial Hospital. Indian J Cancer 40:71–76PubMedGoogle Scholar
  7. 7.
    Malkan UY, Gunes G, Eliacik E, Haznedaroglu IC, Etgul S, Aslan T et al (2015) The factors affecting early death after the initial therapy of acute myeloid leukemia. Int J Clin Exp Med 8:22564PubMedPubMedCentralGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Samaritan HospitalPazhanganad, ErnakulamIndia
  2. 2.Department of PathologyJawaharlal Institute of Postgraduate Medical Education and ResearchPuducherryIndia
  3. 3.Department of MedicineJawaharlal Institute of Postgraduate Medical Education and ResearchPuducherryIndia
  4. 4.Department of MedicineMahatma Gandhi Medical College and Research InstitutePondicherryIndia

Personalised recommendations